ESMO 2019 Congress | OncologyPRO

Abstract 3350

Background

Clinical pathways in oncology have become increasingly complex, involving several different healthcare professionals inside and outside the hospital setting who need particular coordination to provide appropriate care for patients. Very few QI exist to evaluate the oncological clinical pathway in its entirety, particularly regarding the various stages between patient admissions and discharges and the liaisons with non-hospital healthcare professionals (e.g. GPs, pharmacists). Our objective is to select a number of QI describing the oncological clinical pathway with an expert panel.

Methods

A systematic review of available QI describing the oncological clinical pathways in the literature was conducted. The list of selected QI was presented to an expert panel (oncologists, pharmacists and SRNs) of various hospitals in France. The selection involved a two-step process: a preliminary selection was conducted based on the title and rationale of the QI by consensus (nominal group), assigning a value to each QI reviewed on the basis of its appropriateness and its feasibility (1^st working group). The pre-selected QI were then described in detail and presented to the expert panel (2^nd working group) in order to validate the selection.

Results

5731 QI were identified in the literature review and 131 included. 17 indicators were pre-selected by the experts (1^st working group). After presentation of the 17 detailed descriptors, the QIs were clustered or eliminated. Ultimately, 10 QI were selected (Table): outcome (2), process (3) and structure (5).Table: 1658P

QI	Description	Type
1	Symptoms and disease progression	Structure
2	Assessment of tolerance to treatment	Process
3	Management of patients receiving oral therapy	Structure
4	Quality of the liaison document	Process
5	Composite score for supportive care	Structure
6	Patient therapeutic education	Structure
7	Medication reconciliation	Process
8	Unscheduled admissions	Outcome
9	Declaration and follow-up upon serious adverse events in clinical pathway	Structure
10	Patient’s experience (PREMS)	Outcome

Conclusions

This approach will be developed further by presenting the IQs to patient associations and primary care physicians in order to gather their feedback, refine, adapt and ultimately create a representative set of indicators.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Novartis Oncology France.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

30 Sep 2019